RBC Capital Stays on the Sidelines with Bluebird Bio (BLUE) Despite Abecma's Approval

March 29, 2021 7:12 AM EDT
Get Alerts BLUE Hot Sheet
Price: $29.72 --0%

Rating Summary:
    15 Buy, 14 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 9 | Down: 8 | New: 34
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

RBC Capital analyst Luca Issi reiterated a Sector Perform rating and $37.00 price target on bluebird bio (NASDAQ: BLUE) noting the approval of Abecma over the weekend is good news as:
1) it marks the first ever CART approved for multiple myeloma
2) bears were expecting a delay due to COVID-19 disruptions of inspections

The analyst stated "The Label looks relatively clean with only a couple of additional warnings vs CD19 CART (HLH/MAS). Despite the good news, we remain on the sidelines as approval was largely anticipated, BMY retains most of the economics and we await further clarity on SCD/B-thal clinical hold."

For an analyst ratings summary and ratings history on bluebird bio click here. For more ratings news on bluebird bio click here.

Shares of bluebird bio closed at $32.90 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

RBC Capital